VEGFA and neoplasm: Further evidence supporting the idea that VEGF is the downstream effector responsible for the improved blood flow comes from the fact that in the same SQ20B tumor model, the anti-VEGF antibody bevacizumab led to a similar improvement in blood flow (Fig. S1).